Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Next Previous
Trial Profile

My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Cobimetinib (Primary) ; Erlotinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
  • Indications Adenocarcinoma; Adrenocortical carcinoma; Biliary cancer; Bladder cancer; Breast cancer; Carcinoma; Cervical cancer; CNS cancer; Colon cancer; Colorectal cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Leiomyosarcoma; Liver cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Salivary gland cancer; Sarcoma; Skin cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer; Tumours; Urogenital cancer; Uterine cancer
  • Focus Therapeutic Use
  • Acronyms Mypathway
  • Sponsors Genentech

    • Most Recent Events

    • 04 Oct 2023 Results (At data cutoff March 2022, n=346 ) assessing efficacy of Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors published in the Journal of Clinical Oncology
    • 06 Jun 2023 Status changed from active, no longer recruiting to completed.
    • 17 Mar 2023 Planned End Date changed from 29 Sep 2023 to 12 May 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top